Press Releases :: Rigel Pharmaceuticals, Inc. (RIGL)

Jun 04, 2013 2:00am EDT

Rigel Will Resume Responsibility for Fostamatinib Program

May 22, 2013 7:30am EDT

Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye

May 07, 2013 7:30am EDT

Rigel Announces First Quarter 2013 Financial Results

Apr 05, 2013 2:01am EDT

AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis

Mar 05, 2013 7:30am EST

Rigel Announces Fourth Quarter and Year End 2012 Financial Results

Feb 28, 2013 7:30am EST

Rigel Announces Participation at Two Investor Conferences

Feb 07, 2013 7:30am EST

Rigel to Present at BIO CEO & Investor Conference

Jan 03, 2013 7:30am EST

Rigel to Focus on Extensive Clinical Pipeline at Upcoming J.P. Morgan Presentation

Dec 13, 2012 7:30am EST

AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis

Oct 03, 2012 9:28am EDT

Rigel Announces Pricing Of Public Offering Of Common Stock